Výsledky vyhledávání - "Samaniego-Toro D"

Akademický článek

Usage of the Anemia Control Model Is Associated with Reduced Hospitalization Risk in Hemodialysis.

Autor: Garbelli M; Clinical Advanced Analytics, Global Medical Office, Fresenius Medical Care, 26020 Vaiano Cremasco, Italy., Baro Salvador ME; Nephrocare Spain, Fresenius Medical Care, 08013 Barcelona, Spain., Rincon Bello A; Nephrocare Spain, Fresenius Medical Care, 08013 Barcelona, Spain., Samaniego Toro D; Nephrocare Spain, Fresenius Medical Care, 08013 Barcelona, Spain., Bellocchio F; Clinical Advanced Analytics, Global Medical Office, Fresenius Medical Care, 26020 Vaiano Cremasco, Italy., Fumagalli L; Clinical Advanced Analytics, Global Medical Office, Fresenius Medical Care, 26020 Vaiano Cremasco, Italy., Chermisi M; Clinical Advanced Analytics, Global Medical Office, Fresenius Medical Care, 26020 Vaiano Cremasco, Italy., Apel C; Health Economics and Market Access, Fresenius Medical Care, 61352 Bad Homburg, Germany., Petrovic J; Health Economics and Market Access, Fresenius Medical Care, 61352 Bad Homburg, Germany., Kendzia D; Health Economics and Market Access, Fresenius Medical Care, 61352 Bad Homburg, Germany., Ion Titapiccolo J; Clinical Advanced Analytics, Global Medical Office, Fresenius Medical Care, 26020 Vaiano Cremasco, Italy., Yeung J; Clinical Advanced Analytics, Global Medical Office, Fresenius Medical Care, 26020 Vaiano Cremasco, Italy., Barbieri C; Global Digital and Innovation Technology Department, Fresenius Medical Care, 26020 Vaiano Cremasco, Italy., Mari F; Global Digital and Innovation Technology Department, Fresenius Medical Care, 26020 Vaiano Cremasco, Italy., Usvyat L; Clinical Advanced Analytics, Global Medical Office, Fresenius Medical Care, 26020 Vaiano Cremasco, Italy., Larkin J; Clinical Advanced Analytics, Global Medical Office, Fresenius Medical Care, 26020 Vaiano Cremasco, Italy., Stuard S; Clinical and Therapeutic Governance EMEA, Medical Affairs, Global Medical Office, Fresenius Medical Care, 26020 Vaiano Cremasco, Italy., Neri L; Clinical Advanced Analytics, Global Medical Office, Fresenius Medical Care, 26020 Vaiano Cremasco, Italy.

Publikováno v: Biomedicines [Biomedicines] 2024 Sep 28; Vol. 12 (10). Date of Electronic Publication: 2024 Sep 28.

Zobrazit plný text záznamu

Akademický článek

Evaluation of a Liquid Chromatography-Tandem Mass Spectrometry Method for the Analysis of Glucosylceramide and Galactosylceramide Isoforms in Cerebrospinal Fluid of Parkinson's Disease Patients.

Autor: Castillo-Ribelles L; Clinical Biochemistry Department, Vall d'Hebron University Hospital, Barcelona 08035, Spain.; Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT) Research Group, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona 08035, Spain.; Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Barcelona 08193, Spain., Arranz-Amo JA; Clinical Biochemistry Department, Vall d'Hebron University Hospital, Barcelona 08035, Spain.; Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT) Research Group, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona 08035, Spain., Hernández-Vara J; Neurodegenerative Diseases Research Group- Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona 08035, Spain.; Neurology Department, Vall d'Hebron University Hospital, Barcelona 08035, Spain., Samaniego-Toro D; Neurology Department, Vall d'Hebron University Hospital, Barcelona 08035, Spain., Enriquez-Calzada S; Neurodegenerative Diseases Research Group- Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona 08035, Spain., Pozo SL; Neurodegenerative Diseases Research Group- Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona 08035, Spain.; Neurology Department, Vall d'Hebron University Hospital, Barcelona 08035, Spain.; Department of Clinical and Movement Neurosciences, University College London Queen Square Institute of Neurology, London WC1N 3BG, U.K., Camprodon-Gomez M; Neurodegenerative Diseases Research Group- Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona 08035, Spain.; Unit of Hereditary Metabolic Disorders, Internal Medicine Department, Vall d'Hebron University Hospital, Barcelona 08035, Spain., Laguna A; Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Barcelona 08193, Spain.; Neurodegenerative Diseases Research Group- Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona 08035, Spain., Gonzalo MA; Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Barcelona 08193, Spain.; Neurodegenerative Diseases Research Group- Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona 08035, Spain., Ferrer R; Clinical Biochemistry Department, Vall d'Hebron University Hospital, Barcelona 08035, Spain.; Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT) Research Group, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona 08035, Spain.; Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Barcelona 08193, Spain., Martinez-Vicente M; Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Barcelona 08193, Spain.; Neurodegenerative Diseases Research Group- Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona 08035, Spain., Carnicer-Caceres C; Clinical Biochemistry Department, Vall d'Hebron University Hospital, Barcelona 08035, Spain.; Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT) Research Group, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona 08035, Spain.

Publikováno v: Analytical chemistry [Anal Chem] 2024 Aug 06; Vol. 96 (31), pp. 12875-12882. Date of Electronic Publication: 2024 Jul 24.

Zobrazit plný text záznamu

Akademický článek

CO223 The Use of Artificial Intelligence to Guide Medication Dosage Is Associated with Improved Anemia Management and Lower Erythropoietin Stimulating Agents Consumption Among Dialysis Patients

Autor: Garbelli, M., Bellocchio, F., Baro Salvador, M.E., Chermisi, M., Rincon Bello, A., Berdud Godoy, I., Ortego Perez, S., Shkolenko, K., Sobrino Perez, A., Samaniego Toro, D., Apel, C., Petrovic, J., Stuard, S., Barbieri, C., Mari, F., Neri, L.

Publikováno v: In Value in Health June 2023 26(6) Supplement:S57-S57

Zobrazit plný text záznamu

Report

The Dentate Nucleus Is the Clue: Erdheim-Chester Disease as a Cause of Cerebellar Syndrome.

Autor: Samaniego-Toro D; Neurology Department Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona Barcelona Spain., González V; Neurology Department Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona Barcelona Spain., Llauradó Gayete A; Neurology Department Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona Barcelona Spain., Gabaldón Domínguez MA; Pathological Anatomy Department Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona Barcelona Spain., Hernández-Vara J; Neurology Department Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona Barcelona Spain.

Publikováno v: Movement disorders clinical practice [Mov Disord Clin Pract] 2022 Sep 11; Vol. 9 (Suppl 2), pp. S17-S20. Date of Electronic Publication: 2022 Sep 11 (Print Publication: 2022).

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

The impact of supine hypertension on target organ damage and survival in patients with synucleinopathies and neurogenic orthostatic hypotension.

Autor: Palma JA; Department of Neurology, Dysautonomia Center, New York University School of Medicine, New York, NY, USA. Electronic address: josealberto.palmacarazo@nyulangone.org., Redel-Traub G; Department of Neurology, Dysautonomia Center, New York University School of Medicine, New York, NY, USA., Porciuncula A; Department of Neurology, Dysautonomia Center, New York University School of Medicine, New York, NY, USA., Samaniego-Toro D; Department of Neurology, Dysautonomia Center, New York University School of Medicine, New York, NY, USA; Department of Neurology, Hospital Universitario German Trias i Pujol, Badalona, Barcelona, Spain., Millar Vernetti P; Department of Neurology, Dysautonomia Center, New York University School of Medicine, New York, NY, USA., Lui YW; Division of Neuroradiology, Department of Radiology, New York University School of Medicine, New York, NY, USA., Norcliffe-Kaufmann L; Department of Neurology, Dysautonomia Center, New York University School of Medicine, New York, NY, USA., Kaufmann H; Department of Neurology, Dysautonomia Center, New York University School of Medicine, New York, NY, USA. Electronic address: Horacio.Kaufmann@nyulangone.org.

Publikováno v: Parkinsonism & related disorders [Parkinsonism Relat Disord] 2020 Jun; Vol. 75, pp. 97-104. Date of Electronic Publication: 2020 May 18.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání